This is a routine annual meeting with no significant changes or financial implications. Shareholders should review the proxy statement for details on executive compensation and board matters, but no immediate action is required.
KURA drugs
KURA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $8.72entry
- T+1 · 7mo ago +4.82%α +3.61% · $9.14
- T+5 · 7mo ago +12.16%α +8.86% · $9.78
- T+20 · 6mo ago +9.06%α +1.33% · $9.51
- T+60 · 4mo ago +38.99%α +30.07% · $12.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology is holding its annual shareholder meeting to vote on director elections, auditor appointment, executive compensation, and equity plan amendments. This is a routine filing with no material financial impact.
Key Financial Metrics
Key Facts
- Kura Oncology is holding its annual shareholder meeting on June 4, 2026
- Shareholders will vote on the election of three Class III directors
- The board recommends ratification of Ernst & Young as independent auditors
- The board recommends approval of executive compensation (Say-on-Pay)
- The board recommends approval of amendments to the 2014 Equity Incentive Plan and 2015 Employee Stock Purchase Plan
Financial Impact
No material financial impact
Risk Factors
- None identified - this is a standard annual meeting with no controversial proposals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-151363 |
| Document: 0001193125-26-151363-index-headers.html | 0001193125-26-151363 |
| Document: 0001193125-26-151363-index.html | 0001193125-26-151363 |
| Document: 0001193125-26-151363.txt | 0001193125-26-151363 |
Track record
29 reports on KURA
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers